NASTAD Drug Pricing and Access Principles

NASTAD is proud to release a set of drug pricing and access principles to further support its mission to ending the HIV and hepatitis epidemics. Treatment and biomedical prevention advances – and the innovative research and development behind them – have revolutionized our ability to provide lifesaving interventions to millions of people living with, or at risk for, HIV, hepatitis C virus (HCV), and substance use disorders worldwide. HIV antiretrovirals, HCV direct acting antivirals, and opioid reversal drugs are critical public health tools, and our ability to access them both nationally and globally must be considered a public health imperative.

Yet access to these prevention, treatment, and curative medications in the United States has been inefficient, expensive, and profoundly inequitable. Federal, regional, and local efforts to end the HIV and hepatitis epidemics serve as an important catalyst to approach drug pricing and access with the goal of expanding and sustaining robust, evidence-based public health practices. The entire drug pricing and delivery system – including pharmaceutical manufacturers, public and private payers, pharmacy benefit managers (PBMs), and government entities – has a role to play in reducing drug prices, containing health care costs, and improving access.
We intend for these principles to advance NASTAD’s health legislative and policy priorities and, more broadly, to help address the health disparities that have fueled disproportionate access to healthcare in the United States.

NASTAD Drug Pricing Principles